To determine whether the total tumor load (TTL) as indicated through the one-step nucleic acid amplification (OSNA) assay can be a predictive factor of non-sentinel lymph node (SLN) metastasis in early breast cancer patients. Material and Method: The records of 102 patients with cT1-3N0 breast cancer who had an intraoperative SLN evaluation performed through an OSNA assay at Songklanagarind Hospital between 1 January 2015 and 30 May 2016 were examined. Results: Univariate analysis found TTL, tumor size, presence of lymphovascular invasion, and macrometastasis were significant predictive factors of non-SLN metastasis. In the multivariate analysis, TTL was the only predictive factor with statistical significance (OR 1.1, 95% CI=1.0, 1.2). The area under the receiver operating characteristics (ROC) curve of TTL was 0.9 (95% CI=0.8, 0.9). Conclusion: TTL is a significant predictive factor of non-SLN metastasis in early breast cancer patients.
Introduction
The axillary lymph node is the most important prognostic factor in breast cancer patients. The sentinel lymph node (SLN) biopsy is the standard method that can represent overall axillary lymph node status in patients who are clinically negative for lymph nodes. [1] [2] [3] [4] The incidences of non-SLN metastasis in SLN micrometastasis and macrometastasis are 5.0-25.0% and 40.0-60.0%, respectively. 5, 6 The ACOSOG Z0011 trial found that there are some patients with a SLN metastasis in which axillary lymph node dissection (ALND) can be safely omitted as it does not show differences in the locoregional recurrence rates nor in the survival rate. 7 There is still a debate on which patients with a positive SLN can still benefit from ALND.
Numerous studies have been designed to identify variables that are predictive of non-SLN metastasis to avoid the complete ALND. Such studies have shown that different pathological characteristics of the primary tumor and the SLN metastasis are linked with higher chances to find additional positive non-SLN. 8, 9 The traditional intraoperative histological exams are not standardized and have limited ability to detect metastasis. This is due to the partial evaluation of the node, with the risk of leaving a non-identified metastasis, thus underestimating the stage of the lymph node disease. 10, 11 The current method of lymph node metastasis is the One-Step Nucleic Acid Amplification (OSNA) assay (Sysmex Corporation, Kobe, Japan), which does the analysis through the detection and amplification of cytokeratin 19 (CK19) mRNA. This test shows a semi-quantitative result for the detection of nodal metastasis, differentiating micrometastasis from macrometastasis.
The objective of this study was to determine the total tumor load (TTL), which is one of the variables determined with the OSNA assay, and is predictive factor of non-SLN metastasis in breast cancer patients.
Material and Method
The records of 238 SLNs from 102 patients with cT1-T3N0 breast cancer who had SLN analysis by OSNA assay at Songklanagarind Hospital between 1 January 2015 and 30 May 2016 were collected. The records of patients who had undergone systemic neoadjuvant chemotherapy, or who had breast cancer with metastasis at the time of diagnosis, were excluded.
The data collected from the medical records included age, type of surgery, tumor size, tumor site, histologic subtype, grade, estrogen receptor and progesterone receptor status, human epidermal growth factor receptor 2 (HER2) status, presence of lymphovascular invasion, SLN identification technique, turnaround time, total number of SLNs, number of positive and negative SLNs, and number of positive and negative non-SLNs. TTL was calculated as number of CK19 mRNA copies/ μLin the positive SLNs.
SLN evaluation by OSNA assay
The SLNs identification technique using periareolar injection of 1.0% isosulfan blue dye, 99mTc sulfur colloid, or both, depended on the surgeon. SLNs were denoted as blue node, hot node, blue+hot node, and/or palpable node. All whole SLNs were sent for an OSNA assay (Sysmex, Kobe, Japan). The results were assessed by the cut off level of calculated CK19 mRNA copies per μL: macrometastasis was defined as >5,000 copies/μL of CK19 mRNA, micrometastasis as 250-5,000 copies/μL, and non-metastasis as <250 copies/μL. 12 Several studies have found that the OSNA assay could accurately detect SLN metastasis at rates comparable with the conventional pathological examination. [12] [13] [14] [15] Axillary lymph node dissection at levels I and II was done in cases of SLN metastasis.
Statistical analysis
Statistical analysis was done with Statistical Package for the Social Science (SPSS) for Windows version 17.0 (SPSS Inc., Chicago, IL, United States). Categorical data were analyzed by Pearson's chi-square test. Continuous variables were analyzed by Mann-Whitney U-test. In SLN positive patients, univariate and multivariate logistic regression models were used to evaluate the risk factors that were different between the non-SLN positive and negative groups. The power of the TTL was quantified with a receiver operating characteristics (ROC) curve as measured by the areas under receiver operating characteristic curves (AUC). A p-value of <0.050 indicates statistical significance. All tests were two-tailed with a 95% confidence interval.
Results
A total of 238 SLNs from 102 patients were examined. Almost 80.0% of the patients were more than 45 years old, and all had a tumor size less than 5 cm (<T3 lesion) except for one patient with a 6 cm tumor. Thirty-nine patients (38.0%) had SLN metastasis. The average number of SLNs removed in the groups with negative and positive SLNs were 2.4 and 2.2 respectively. Patients and disease characteristics divided by negative and positive SLNs are reported in Table 1 .
In patients with ALND after positive SLN, 25 patients (64.0%) had no additional axillary lymph node metastasis. Fourteen patients had additional non-SLN metastasis. In the SLN metastasis without additional non-SLN metastasis group, 17 patients (68.0%) had a micrometastasis (OSNA+) and 8 patients (32.0%) had a macrometastasis (OSNA++) in the SLN. Nineteen patients had only one positive SLN in the SLN metastasis without additional non-SLN metastasis group. Only 2 patients had 4 positive SLNs in the intraoperative evaluation. The characteristics of the patients who had an ALND are described in Table 2 . 
Prediction of non-SLN Metastasis by OSNA Assay in Breast Cancer

Univariate and multivariate analysis of non-SLN metastasis
The univariate analysis included age, tumor site, type of breast surgery, SLN identification technique, average number of SLNs, turnaround time, tumor size, histologic type, estrogen receptor (ER), progesterone receptor (PR), HER2 status, lymphovascular invasion (LVI) status, type of SLN metastasis, number of positive SLNs, and the number of TTL in the SLN. The TTL (p-value=0.040, OR= 1.1, 95% CI=1.0, 1.2), tumor size (p-value=0.021, OR=3.4, 95% CI=1. 2, 9.6) , presence of lymphovascular invasion (p-value=0.043, OR=4.3, 95% CI=1. 1, 17.4) , and macrometastasis in the SLN (p-value=0.004, OR=12.7, 95% CI= 2.2, 70.9) were statistically significant predictive factors of non-SLN metastasis.
The TTL was the only predictive factor of non-SLN metastasis in the multivariate analysis (OR=1.1, 95% CI= 1.0, 1.2), p-value=0.042 ( Table 3 ).
The power of the TTL, quantified with the ROC curve as measured by the AUC, was 0.9 (95% CI=0.8, 0.9) ( Figure 1 ). Figure 1 The power of the total tumor load analysed against the occurrence of tumor metastasis, in non-sentinel lymph nodes quantified with the receiver operating characteristics curve as measured by the area under curve, was 0.9
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Discussion
Intraoperative assessment of SLN by OSNA assay is a simple and effective technique which is more sensitive than frozen section and touch imprint cytology. [16] [17] [18] When compared with the conventional histology in Songklanagarind Hospital, the OSNA assay had a sensitivity of 100.0%, specificity 95.2%, positive predictive value 73.5%, and negative predictive value 100.0%.
To avoid sampling errors, the concept of whole SLN analysis was reported as standard technique. 19 It also shows a quantitative result of the TTL. [22] [23] [24] [25] Several studies have reported on significant predictive factors of additional non-SLN metastasis in patients with positive SLN who met the ACOSOG Z0011 trial but may not have completely met all the criteria of the research study. A study by Mittendorf et al. 26 tested 6 variables: number of SLNs identified, number of positive SLNs, SLN metastasis size, extranodal extension, tumor size, and histology in an MD Anderson nomogram for predicting the likelihood of having additional axillary metastasis. The main problem is the results of these variables revealed after surgery in postoperative period.
The TTL model, which was used to intraoperatively evaluate the likelihood of metastasis in positive SLN, was generated as a new predictor. Espinosa-Bravo et al. 27 reported that TTL and hormonal status were statistically significant predictive factors for non-SLN metastasis. Peg et al. 28 found that TTL, tumor size, number of affected SLNs, HER2 status and LVI were predictors of axillary status. Our study found that only TTL was a significant predictive factor for additional non-SLN metastasis, while the size of SLN metastasis, hormonal status, tumor size, number of affected SLNs, HER2 status and LVI did not have statistical significance. The TTL was quantified by the AUC, with a value of 0.9 (95% CI=0.8, 0.9).
Our study had an important limitation, which was the low number of positive SLN cases. Further studies with l arger number of cases are necessary to find a reliable TTL cut-off point for determining non-SLN metastasis.
Conclusion
The TTL as assessed intraoperatively by whole SLN analysis is a diagnostic technique for predicting additional non-SLN metastasis that can help surgeons to make timely decisions concerning ALND for their patients. The limitation of this study was the low number of positive SLN cases.
